Impact of epidermal growth factor receptor protein and gene alteration on <scp>T</scp>aiwanese hepatocellular carcinomas

Su, Yu-Hung; Ng, Kwai‐Fong; Yu, Ming–Chin; Wu, Ting-Jung; Yeh, Ta‐Sen; Lee, Wei‐Chen; Lin, Yi-Jyun; Hsieh, Tsung‐Han; Lin, Chun‐Yen; Yeh, Chau‐Ting; Chen, Tse–Ching

doi:10.1111/jgh.12944

Cited by 3 publications

(1 citation statement)

References 34 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that GE11 could mediate passage of conjugated liposomes through the cell membrane [ 34 – 36 ]. EGFR is overexpressed on the surface of many carcinoma cells, including HCC [ 37 , 38 ]. Therefore, in this study, we crosslinked the GE11 polypeptide to the surface of MS2 VLPs, thus rendering them target EGFR-positive cells.…”

Section: Introductionmentioning

confidence: 99%

Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed cancers worldwide. However, the treatment of patients with HCC is particularly challenging. Long non-coding RNA maternally expressed gene 3 (MEG3) has been identified as a potential suppressor of several types of tumors, but the delivery of long RNA remains problematic, limiting its applications. In the present study, we designed a novel delivery system based on MS2 virus-like particles (VLPs) crosslinked with GE11 polypeptide. This vector was found to be fast, effective and safe for the targeted delivery of lncRNA MEG3 RNA to the epidermal growth factor receptor (EGFR)-positive HCC cell lines without the activation of EGFR downstream pathways, and significantly attenuated both in vitro and in vivo tumor cell growth. Our study also revealed that the targeted delivery was mainly dependent on clathrin-mediated endocytosis and MEG3 RNA suppresses tumor growth mainly via increasing the expression of p53 and its downstream gene GDF15, but decreasing the expression of MDM2. Thus, this vector is promising as a novel delivery system and may facilitate a new approach to lncRNA based cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization

Adhoute¹,

Pénaranda

Raoul³

et al. 2017

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

et al. 2018

View full text Add to dashboard Cite

Objectives: To investigate the clinical efficacy and tolerability of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Methods: A total of 90 patients with advanced HCC, Child-Pugh class A–B7 cirrhosis, and no prior systemic therapy were randomly assigned (1: 1) to receive either 10 mg/kg B intravenously every 14 days and 150 mg E orally daily (n = 47) (B+E) or 400 mg S orally twice daily (n = 43). The primary endpoint was overall survival (OS). Secondary endpoints included event-free survival (EFS), objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1), time to progression, and safety and tolerability. Results: The median OS was 8.55 months (95% CI: 7.00–13.9) for patients treated with B+E and 8.55 months (95% CI: 5.69–12.2) for patients receiving S. The hazard ratio (HR) for OS was 0.92 (95% CI: 0.57–1.47). The median EFS was 4.37 months (95% CI: 2.99–7.36) for patients receiving B+E and 2.76 months (95% CI: 1.84–4.80) for patients receiving S. The HR for EFS was 0.67 (95% CI: 0.42–1.07; p = 0.09), favoring B+E over S. When OS was assessed among patients who were Child-Pugh class A, the median OS was 11.4 months (95% CI: 7.5–15.7) for patients treated with B+E (n = 39) and 10.26 months (95% CI: 5.9–13.0) for patients treated with S (n = 38) (HR = 0.88; 95% CI: 0.53–1.46). Conclusions: There was no difference in efficacy between the B+E and S arms, although the safety and tolerability profile tended to favor B+E over S based on competing risk analysis.

show abstract

Impact of epidermal growth factor receptor protein and gene alteration on Taiwanese hepatocellular carcinomas

Abstract: EGFR CNG was related to crucial clinicopathological features and early recurrence, indicating that EGFR CNG might be a poor prognosis factor for Taiwanese HCC.

Cited by 3 publications

References 34 publications

Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma

Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma

NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

Contact Info

Product

Resources

About